|
Gluck, M R; Moy, L Y; Jayatilleke, E et al. (2001) Parallel increases in lipid and protein oxidative markers in several mouse brain regions after methamphetamine treatment. J Neurochem 79:152-60
|
|
Hogan, K A; Staal, R G; Sonsalla, P K (2000) Analysis of VMAT2 binding after methamphetamine or MPTP treatment: disparity between homogenates and vesicle preparations. J Neurochem 74:2217-20
|
|
Moy, L Y; Albers, D S; Sonsalla, P K (1998) Lowering ambient or core body temperature elevates striatal MPP+ levels and enhances toxicity to dopamine neurons in MPTP-treated mice. Brain Res 790:264-9
|
|
Albers, D S; Zeevalk, G D; Sonsalla, P K (1996) Damage to dopaminergic nerve terminals in mice by combined treatment of intrastriatal malonate with systemic methamphetamine or MPTP. Brain Res 718:217-20
|
|
Albers, D S; Sonsalla, P K (1995) Methamphetamine-induced hyperthermia and dopaminergic neurotoxicity in mice: pharmacological profile of protective and nonprotective agents. J Pharmacol Exp Ther 275:1104-14
|
|
Delle Donne, K T; Sonsalla, P K (1994) Protection against methamphetamine-induced neurotoxicity to neostriatal dopaminergic neurons by adenosine receptor activation. J Pharmacol Exp Ther 271:1320-6
|
|
Terleckyj, I; Sonsalla, P K (1994) The sigma receptor ligand (+/-)-BMY 14802 prevents methamphetamine-induced dopaminergic neurotoxicity via interactions at dopamine receptors. J Pharmacol Exp Ther 269:44-50
|
|
Sonsalla, P K; Riordan, D E; Heikkila, R E (1991) Competitive and noncompetitive antagonists at N-methyl-D-aspartate receptors protect against methamphetamine-induced dopaminergic damage in mice. J Pharmacol Exp Ther 256:506-12
|
